DexCom Net Worth
DexCom Net Worth Breakdown | DXCM |
DexCom Net Worth Analysis
DexCom's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including DexCom's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of DexCom's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform DexCom's net worth analysis. One common approach is to calculate DexCom's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares DexCom's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing DexCom's net worth. This approach calculates the present value of DexCom's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of DexCom's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate DexCom's net worth. This involves comparing DexCom's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into DexCom's net worth relative to its peers.
Enterprise Value |
|
To determine if DexCom is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding DexCom's net worth research are outlined below:
| DexCom Inc is unlikely to experience financial distress in the next 2 years | |
| DexCom Inc has a strong financial position based on the latest SEC filings | |
| Over 96.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: 4 Seniors Aging Demographics Stocks to Watch Right Now |
DexCom uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in DexCom Inc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to DexCom's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 25th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
DexCom Target Price Consensus
DexCom target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. DexCom's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 25 | Strong Buy |
Most DexCom analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand DexCom stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of DexCom Inc, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationDexCom Target Price Projection
DexCom's current and average target prices are 89.91 and 96.26, respectively. The current price of DexCom is the price at which DexCom Inc is currently trading. On the other hand, DexCom's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On DexCom Target Price
Know DexCom's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as DexCom is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading DexCom Inc backward and forwards among themselves. DexCom's institutional investor refers to the entity that pools money to purchase DexCom's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 6.9 M | Amvescap Plc. | 2024-12-31 | 5 M | Norges Bank | 2024-12-31 | 5 M | Amundi | 2024-12-31 | 4.6 M | Bank Of New York Mellon Corp | 2024-12-31 | 4.2 M | Northern Trust Corp | 2024-12-31 | 4.1 M | Capital World Investors | 2024-12-31 | 3.8 M | D. E. Shaw & Co Lp | 2024-12-31 | 3.5 M | American Century Companies Inc | 2024-12-31 | 3.4 M | Vanguard Group Inc | 2024-12-31 | 46.5 M | Blackrock Inc | 2024-12-31 | 39.6 M |
Follow DexCom's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 34.51 B.Market Cap |
|
Project DexCom's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.09 | 0.10 | |
| Return On Capital Employed | 0.17 | 0.18 | |
| Return On Assets | 0.09 | 0.09 | |
| Return On Equity | 0.27 | 0.29 |
When accessing DexCom's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures DexCom's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of DexCom's profitability and make more informed investment decisions.
Evaluate DexCom's management efficiency
DexCom Inc has return on total asset (ROA) of 0.0588 % which means that it generated a profit of $0.0588 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2763 %, meaning that it created $0.2763 on every $100 dollars invested by stockholders. DexCom's management efficiency ratios could be used to measure how well DexCom manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of February 2025, Return On Tangible Assets is likely to grow to 0.1. Also, Return On Capital Employed is likely to grow to 0.18. At this time, DexCom's Net Tangible Assets are very stable compared to the past year. As of the 26th of February 2025, Intangible Assets is likely to grow to about 108.6 M, while Asset Turnover is likely to drop 0.56.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.20 | 5.46 | |
| Tangible Book Value Per Share | 4.88 | 5.13 | |
| Enterprise Value Over EBITDA | 39.72 | 41.70 | |
| Price Book Value Ratio | 14.97 | 10.08 | |
| Enterprise Value Multiple | 39.72 | 41.70 | |
| Price Fair Value | 14.97 | 10.08 | |
| Enterprise Value | 30.1 B | 31.6 B |
DexCom showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Enterprise Value Revenue 8.7951 | Revenue | Quarterly Revenue Growth 0.076 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific DexCom insiders, such as employees or executives, is commonly permitted as long as it does not rely on DexCom's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases DexCom insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
DexCom Corporate Filings
ASR | 18th of February 2025 Automatic Shelf Registration Statement under Rule 415 filed with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
8K | 13th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 30th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 6th of December 2024 An amended filing to the original Schedule 13G | ViewVerify |
DexCom Earnings Estimation Breakdown
The calculation of DexCom's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of DexCom is estimated to be 0.3273 with the future projection ranging from a low of 0.28 to a high of 0.43. Please be aware that this consensus of annual earnings estimates for DexCom Inc is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.28 Lowest | Expected EPS | 0.43 Highest |
DexCom Earnings Projection Consensus
Suppose the current estimates of DexCom's value are higher than the current market price of the DexCom stock. In this case, investors may conclude that DexCom is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and DexCom's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 24 | 83.69% | 0.45 | 0.3273 | 1.42 |
DexCom Earnings per Share Projection vs Actual
Actual Earning per Share of DexCom refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering DexCom Inc predict the company's earnings will be in the future. The higher the earnings per share of DexCom, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.DexCom Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as DexCom, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of DexCom should always be considered in relation to other companies to make a more educated investment decision.DexCom Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact DexCom's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-06 | 2024-12-31 | 0.52 | 0.45 | -0.07 | 13 | ||
2024-10-24 | 2024-09-30 | 0.44 | 0.45 | 0.01 | 2 | ||
2024-07-25 | 2024-06-30 | 0.39 | 0.43 | 0.04 | 10 | ||
2024-04-25 | 2024-03-31 | 0.27 | 0.32 | 0.05 | 18 | ||
2024-02-08 | 2023-12-31 | 0.43 | 0.5 | 0.07 | 16 | ||
2023-10-26 | 2023-09-30 | 0.34 | 0.5 | 0.16 | 47 | ||
2023-07-27 | 2023-06-30 | 0.23 | 0.34 | 0.11 | 47 | ||
2023-04-27 | 2023-03-31 | 0.15 | 0.17 | 0.02 | 13 | ||
2023-02-09 | 2022-12-31 | 0.27 | 0.34 | 0.07 | 25 | ||
2022-10-27 | 2022-09-30 | 0.24 | 0.28 | 0.04 | 16 | ||
2022-07-28 | 2022-06-30 | 0.19 | 0.17 | -0.02 | 10 | ||
2022-04-28 | 2022-03-31 | 0.13 | 0.08 | -0.05 | 38 | ||
2022-02-10 | 2021-12-31 | 0.21 | 0.17 | -0.04 | 19 | ||
2021-10-28 | 2021-09-30 | 0.16 | 0.22 | 0.06 | 37 | ||
2021-07-29 | 2021-06-30 | 0.11 | 0.19 | 0.08 | 72 | ||
2021-04-29 | 2021-03-31 | 0.07 | 0.08 | 0.01 | 14 | ||
2021-02-11 | 2020-12-31 | 0.23 | 0.23 | 0.0 | 0 | ||
2020-10-27 | 2020-09-30 | 0.16 | 0.24 | 0.08 | 50 | ||
2020-07-28 | 2020-06-30 | 0.09 | 0.2 | 0.11 | 122 | ||
2020-04-28 | 2020-03-31 | 0.04 | 0.11 | 0.07 | 175 | ||
2020-02-13 | 2019-12-31 | 0.18 | 0.29 | 0.11 | 61 | ||
2019-11-06 | 2019-09-30 | 0.05 | 0.16 | 0.11 | 220 | ||
2019-07-31 | 2019-06-30 | 0.01 | 0.02 | 0.01 | 100 | ||
2019-05-01 | 2019-03-31 | -0.04 | -0.01 | 0.03 | 75 | ||
2019-02-21 | 2018-12-31 | 0.04 | 0.14 | 0.1 | 250 | ||
2018-11-06 | 2018-09-30 | -0.02 | 0.04 | 0.06 | 300 | ||
2018-08-01 | 2018-06-30 | -0.05 | -0.02 | 0.03 | 60 | ||
2018-05-02 | 2018-03-31 | -0.08 | -0.08 | 0.0 | 0 | ||
2018-02-27 | 2017-12-31 | 0.01 | 0.03 | 0.02 | 200 | ||
2017-11-01 | 2017-09-30 | -0.04 | -0.01 | 0.03 | 75 | ||
2017-08-01 | 2017-06-30 | -0.05 | -0.04 | 0.01 | 20 | ||
2017-05-02 | 2017-03-31 | -0.13 | -0.12 | 0.01 | 7 | ||
2017-02-28 | 2016-12-31 | -0.02 | -0.02 | 0.0 | 0 | ||
2016-11-01 | 2016-09-30 | -0.03 | -0.05 | -0.02 | 66 | ||
2016-08-02 | 2016-06-30 | -0.03 | -0.06 | -0.03 | 100 | ||
2016-04-27 | 2016-03-31 | -0.05 | -0.06 | -0.01 | 20 | ||
2016-02-23 | 2015-12-31 | 0.01 | 0.01 | 0.0 | 0 | ||
2015-08-05 | 2015-06-30 | -0.01 | -0.01 | 0.0 | 0 | ||
2015-04-29 | 2015-03-31 | -0.03 | -0.04 | -0.01 | 33 | ||
2015-02-25 | 2014-12-31 | -0.01 | 0.01 | 0.02 | 200 | ||
2014-11-06 | 2014-09-30 | -0.01 | -0.02 | -0.01 | 100 | ||
2014-08-06 | 2014-06-30 | -0.03 | -0.02 | 0.01 | 33 | ||
2014-05-01 | 2014-03-31 | -0.02 | -0.04 | -0.02 | 100 | ||
2014-02-20 | 2013-12-31 | -0.02 | -0.01 | 0.01 | 50 | ||
2013-11-06 | 2013-09-30 | -0.03 | -0.02 | 0.01 | 33 | ||
2013-08-07 | 2013-06-30 | -0.04 | -0.04 | 0.0 | 0 | ||
2013-05-01 | 2013-03-31 | -0.04 | -0.04 | 0.0 | 0 | ||
2013-02-21 | 2012-12-31 | -0.04 | -0.03 | 0.01 | 25 | ||
2012-11-01 | 2012-09-30 | -0.05 | -0.06 | -0.01 | 20 | ||
2012-08-06 | 2012-06-30 | -0.05 | -0.05 | 0.0 | 0 | ||
2012-05-02 | 2012-03-31 | -0.05 | -0.05 | 0.0 | 0 | ||
2012-02-23 | 2011-12-31 | -0.04 | -0.04 | 0.0 | 0 | ||
2011-11-02 | 2011-09-30 | -0.04 | -0.05 | -0.01 | 25 | ||
2011-08-03 | 2011-06-30 | -0.03 | -0.03 | 0.0 | 0 | ||
2011-05-03 | 2011-03-31 | -0.05 | -0.05 | 0.0 | 0 | ||
2011-03-03 | 2010-12-31 | -0.05 | -0.04 | 0.01 | 20 | ||
2010-11-04 | 2010-09-30 | -0.04 | -0.06 | -0.02 | 50 | ||
2010-08-03 | 2010-06-30 | -0.05 | -0.05 | 0.0 | 0 | ||
2010-05-05 | 2010-03-31 | -0.06 | -0.07 | -0.01 | 16 | ||
2010-03-09 | 2009-12-31 | -0.07 | -0.06 | 0.01 | 14 | ||
2009-11-04 | 2009-09-30 | -0.08 | -0.07 | 0.01 | 12 | ||
2009-08-03 | 2009-06-30 | -0.08 | -0.08 | 0.0 | 0 | ||
2009-05-06 | 2009-03-31 | -0.08 | -0.08 | 0.0 | 0 | ||
2009-03-05 | 2008-12-31 | -0.11 | -0.11 | 0.0 | 0 | ||
2008-11-10 | 2008-09-30 | -0.12 | -0.12 | 0.0 | 0 | ||
2008-08-05 | 2008-06-30 | -0.11 | -0.12 | -0.01 | 9 | ||
2008-05-08 | 2008-03-31 | -0.1 | -0.11 | -0.01 | 10 | ||
2008-03-11 | 2007-12-31 | -0.1 | -0.11 | -0.01 | 10 | ||
2007-10-30 | 2007-09-30 | -0.1 | -0.1 | 0.0 | 0 | ||
2007-07-30 | 2007-06-30 | -0.1 | -0.1 | 0.0 | 0 | ||
2007-05-09 | 2007-03-31 | -0.1 | -0.1 | 0.0 | 0 | ||
2007-02-27 | 2006-12-31 | -0.12 | -0.1 | 0.02 | 16 | ||
2006-10-23 | 2006-09-30 | -0.1 | -0.12 | -0.02 | 20 | ||
2006-07-20 | 2006-06-30 | -0.11 | -0.1 | 0.01 | 9 | ||
2006-05-15 | 2006-03-31 | -0.12 | -0.11 | 0.01 | 8 | ||
2006-02-27 | 2005-12-31 | -0.07 | -0.12 | -0.05 | 71 | ||
2005-11-01 | 2005-09-30 | -0.07 | -0.06 | 0.01 | 14 | ||
2005-08-02 | 2005-06-30 | -0.06 | -0.07 | -0.01 | 16 |
DexCom Corporate Management
| Shelly Selvaraj | Senior Officer | Profile | |
| Leverne Marsh | Executive Marketing | Profile | |
| Matthew Dolan | Corporate Strategy | Profile | |
| Teri Lawver | Executive Officer | Profile | |
| Donald Abbey | Quality Services | Profile | |
| Jereme Sylvain | CFO VP | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.39) | Earnings Share 1.42 | Revenue Per Share | Quarterly Revenue Growth 0.076 | Return On Assets |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.